Project Details
Description
PROJECT SUMMARY/ABSTRACT
Leukemia therapy remains challenging and options are limited for a large fraction of patients who relapse.
Growing evidence suggests that the therapy outcome and failure in myeloid leukemias are intimately linked
to properties of leukemic stem cells (LSCs). Quiescence is a fundamental property shared between LSCs
and normal hematopoietic stem cells (HSCs). Thus, targeting quiescent leukemic stem cells is essential for a
successful long-lasting leukemia therapy. Achieving this goal requires identification of building blocks of stem
cell quiescence and an in-depth understanding of mechanisms that wire them together. By exploiting
mitochondrial heterogeneity we identified discrete deeply quiescent and potent subsets of mouse and human
HSCs. This led us to our discovery that lysosomal activity is heterogeneous in HSCs and key in maintaining
their quiescence. We find lysosomes retain damaged mitochondria and that they are critical to the
maintenance of HSC quiescence and metabolism. We have extended these studies to myeloid leukemias,
using both a mouse model of pre-leukemia and leukemia as well as leukemic patients’ samples and find that
leukemic stem cell populations are heterogeneous distinctively in their lysosomal and mitochondrial
properties. Based on our combined results we propose to investigate the implications of lysosomal
heterogeneity for LSC isolation, generation and maintenance. In Aim 1, we will take advantage of combined
lysosomal and mitochondrial heterogeneity to select LSCs subsets for further investigating their distinct
function related to their lysosomal and mitochondrial alterations; in Aim 2, we will investigate the modulation
of lysosomal-mediated metabolic pathways in LSC subsets; and in Aim 3, we will investigate the potential of
dysregulated lysosomes in mediating the generation of pre-leukemic stem cells. Altogether these studies are
likely to improve our approaches for isolating LSCs and our understanding of LSC generation and
maintenance.
Status | Active |
---|---|
Effective start/end date | 1/09/16 → 31/08/23 |
Funding
- National Cancer Institute: $401,375.00
- National Cancer Institute: $386,619.00
- National Cancer Institute: $375,019.00
- National Cancer Institute: $386,619.00
- National Cancer Institute: $386,619.00
- National Cancer Institute: $386,619.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.